Literature DB >> 16329159

Pharmacogenetics of drug-induced arrhythmias: a feasibility study using spontaneous adverse drug reactions reporting data.

Marie L De Bruin1, Eugene P van Puijenbroek, Madelon Bracke, Arno W Hoes, Hubert G M Leufkens.   

Abstract

PURPOSE: The bottleneck in pharmacogenetic research on rare adverse drug reactions (ADR) is retrieval of patients. Spontaneous reports of ADRs may form a useful source of patients. We investigated the feasibility of a pharmacogenetic study, in which cases were selected from the database of a spontaneous reporting system for ADRs, using drug-induced arrhythmias as an example.
METHODS: Reports of drug-induced arrhythmias to proarrhythmic drugs were selected from the database of the Netherlands Pharmacovigilance Centre (1996-2003). Information on the patient's general practitioner (GP) was obtained from the original report, or from another health care provider who reported the event. GPs were contacted and asked to recruit the patient as well as two age, gender and drug matched controls. Patients were asked to fill a questionnaire and provide a buccal swab DNA sample through the mail. DNA samples were screened for 10 missense mutations in 5 genes associated with the congenital long-QT (LQT) syndrome (KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2).
RESULTS: We identified 45 eligible cases, 29 GPs could be contacted of which seven were willing to participate. Four cases and five matched controls could be included in the study, giving an overall participation rate of 9% (4/45). The main reason for GPs not being willing to participate was lack of time. Variants were identified in KCNH2, SCN5A and KCNE1.
CONCLUSIONS: Spontaneous reporting systems for ADRs may be used for pharmacogenetic research. The methods described, however, need to be improved to increase participation and international collaboration may be required. Copyright 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16329159     DOI: 10.1002/pds.1194

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  6 in total

1.  QTc prolongation in short-term treatment of schizophrenia patients: effects of different antipsychotics and genetic factors.

Authors:  Ilja Spellmann; Matthias A Reinhard; Diana Veverka; Peter Zill; Michael Obermeier; Sandra Dehning; Rebecca Schennach; Norbert Müller; Hans-Jürgen Möller; Michael Riedel; Richard Musil
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-02-10       Impact factor: 5.270

2.  Adverse drug reaction reporting by patients in the Netherlands: three years of experience.

Authors:  Joyce de Langen; Florence van Hunsel; Anneke Passier; Lolkje de Jong-van den Berg; Kees van Grootheest
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

3.  Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in Southwest France.

Authors:  Mariam Molokhia; Atul Pathak; Maryse Lapeyre-Mestre; Laetitia Caturla; Jean Louis Montastruc; Paul McKeigue
Journal:  Br J Clin Pharmacol       Date:  2008-07-15       Impact factor: 4.335

4.  Spontaneous ADR reports as a trigger for pharmacogenetic research: a prospective observational study in the Netherlands.

Authors:  Eugène van Puijenbroek; Jean Conemans; Kees van Grootheest
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 5.  Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update.

Authors:  Maartje N Niemeijer; Marten E van den Berg; Mark Eijgelsheim; Peter R Rijnbeek; Bruno H Stricker
Journal:  Drug Saf       Date:  2015-10       Impact factor: 5.606

6.  Time-to-Onset Analysis of Drug-Induced Long QT Syndrome Based on a Spontaneous Reporting System for Adverse Drug Events.

Authors:  Sayaka Sasaoka; Toshinobu Matsui; Yuuki Hane; Junko Abe; Natsumi Ueda; Yumi Motooka; Haruna Hatahira; Akiho Fukuda; Misa Naganuma; Shiori Hasegawa; Yasutomi Kinosada; Mitsuhiro Nakamura
Journal:  PLoS One       Date:  2016-10-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.